Cargando…
Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients
Alopecia Universalis (AU) is the most severe form of Alopecia Areata and is caused by cytotoxic T-cells reacting with follicular autoantigens, producing complete loss of scalp and body hair. Alemtuzumab is a highly efficacious monoclonal antibody used in the treatment of Multiple Sclerosis (MS), but...
Autores principales: | Borriello, Giovanna, Ianniello, Antonio, Toosy, Ahmed T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305636/ https://www.ncbi.nlm.nih.gov/pubmed/34299789 http://dx.doi.org/10.3390/ijerph18147338 |
Ejemplares similares
-
Alemtuzumab-induced alopecia universalis and transient accommodation
spasm in a patient with multiple sclerosis
por: Tzanetakos, Dimitrios, et al.
Publicado: (2022) -
Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature
por: Zimmermann, Julian, et al.
Publicado: (2017) -
Multiple Autoimmune Syndrome With Alopecia Universalis and Immune Thrombocytopenic Purpura
por: Alwasaidi, Turki A, et al.
Publicado: (2021) -
Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up
por: Hyun, Jae-Won, et al.
Publicado: (2019) -
Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine
por: Shohdy, Kyrillus S, et al.
Publicado: (2018)